局部晚期中央型/超中央型非小细胞肺癌常规放化疗联合立体定向推量的EQD2可行性
基于一项已报道的1期试验(n=26)的剂量学分析,评估局部晚期非小细胞肺癌接受常规放化疗联合立体定向推量后危及器官的累积EQD2及其与毒性的相关性。初步提出近端支气管血管树D1cc<150 Gy*2*和食管D1cc<100 Gy*10*的剂量约束,正在2期试验(NCT06627738)中前瞻性评估。
要点
- 全组26例中77%为超中央型肿瘤,出现3级、4级、5级毒性各1例。
- 近端支气管血管树D1cc<150 Gy*2*与食管D1cc<100 Gy*10*未见严重晚期毒性。
- 上述约束为初步结果,正在2期试验NCT06627738中前瞻性评估。
核心结论
- 近端支气管血管树D1cc<150 Gy*2*和食管D1cc<100 Gy*10*的初步剂量约束可能是安全的,正在2期试验中前瞻性评估。
- 毒性与此前肿瘤对危及器官浸润程度的相关性仍需进一步前瞻性评估。
研究设计与样本
- 纳入既往已报道的1期试验(PMID: 29650404)患者共26例。
- 患者接受放化疗(顺铂为基础化疗联合23×2 Gy三维适形放疗)后行立体定向推量(3×7-12 Gy)。
主要发现
- 全组26例中77%肿瘤为超中央型、19%为周围型、4%为中央型。
- 观察到1例3级毒性(支气管狭窄/纤维化)、1例4级毒性(食管炎伴瘘)和1例5级毒性(致死性咯血)。
- 危及器官中位最大EQD2 D1cc:主动脉84.3 Gy*3*(范围53.3-190.6),肺动脉136.9 Gy*3*(范围47.2-232.3)。
- 上腔静脉70.6 Gy*3*(范围16.2-192.8),肺静脉69.0 Gy*3*(范围3.5-231),食管67.9 Gy*10*(范围15.7-161)。
- 近端支气管血管树中位最大EQD2 D1cc为153.4 Gy*2*(范围20.3-235.9)。
关键数值与推荐
- 近端支气管血管树D1cc<150 Gy*2*时未见严重晚期毒性。
- 食管D1cc<100 Gy*10*时未见严重晚期毒性。
临床怎么用
- 对局部晚期中央型/超中央型非小细胞肺癌行常规放化疗联合立体定向推量时,可参考近端支气管血管树D1cc<150 Gy*2*和食管D1cc<100 Gy*10*的初步约束。
- 该约束尚属初步,应结合正在进行的2期试验(NCT06627738)结果使用。
局限性
- 为1期试验的回顾性剂量学分析,样本量小(n=26)。
- 剂量约束为初步结果,尚待前瞻性2期试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to evaluate the cumulative equivalent dose in 2 Gy fractions (EQD2) to organs at risk and its potential correlation with toxicities in patients with locally advanced nonsmall cell lung cancer treated with very high mediastinal radiation therapy doses using mixed fractionation. METHODS AND MATERIALS: Patients from a previously reported phase 1 trial (PMID: 29650404) were included (n = 26). They received a stereotactic boost (3 × 7-12 Gy) following chemoradiation therapy (cisplatin-based chemotherapy and 23 × 2 Gy using three-dimensional conformal radiation therapy). Seventeen treatment plans were available for dosimetric analysis. Doses delivered at each point of the planning computed tomography scan from each treatment phase were converted to EQD2 based on the α:β ratios, which are shown in asterisks following each converted dose. The 3-dimensional conformal radiation therapy and stereotactic body radiation therapy plans were each converted to EQD2, and their summation was used to estimate the total dose delivered to organs at risk. RESULTS: In the entire cohort (n = 26), 77% of tumors were ultracentral, 19% peripheral, and 4% central. We observed 1 grade 3 toxicity (bronchial stenosis/fibrosis), 1 grade 4 toxicity (esophagitis with fistula), and 1 grade 5 toxicity (fatal hemoptysis). Dosimetric evaluation of the proximal bronchovascular (PBV) tree and esophagus revealed no severe late toxicity with PBV tree D1cc < 150 Gy *2* and esophageal D1cc < 100 Gy *10*. Median maximal EQD2 D1cc for organs at risk were as follows: aorta, 84.3 Gy *3* (range, 53.3-190.6); pulmonary arteries, 136.9 Gy *3* (range, 47.2-232.3); superior vena cava, 70.6 Gy *3* (range, 16.2-192.8); pulmonary veins, 69.0 Gy *3* (range, 3.5-231); esophagus, 67.9 Gy *10* (range, 15.7-161); PBV tree, 153.4 Gy *2* (range, 20.3-235.9). CONCLUSIONS: The following preliminary dose constraints-PBV tree D1cc < 150 Gy *2* and esophageal D1cc < 100 Gy *10*-may be safe and are currently being prospectively evaluated in an ongoing phase 2 trial (NCT06627738). The correlation between toxicities and the degree of initial tumor infiltration of organs at risk requires further prospective evaluation.
引用
- Gueiderikh A, Lhomel B, Schiappa R, et al. Feasibility of Very High Cumulative Equivalent Dose in 2 Gy Fraction in Locally Advanced Central/Ultracentral Nonsmall Cell Lung Cancer Treated With Conventional Chemoradiation Therapy and a Stereotactic Boost. Adv Radiat Oncol. 2025. PMID: 41404491. doi:10.1016/j.adro.2025.101925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。